aluates Reports

$ 0.0

Automative

Global Chronic Hepatitis B Treatment Oral Drugs Market Research Report 2026

Published Date: 2026-04-13

Report Code: QYRE-Auto-13N17276

Global Chronic Hepatitis B Treatment Oral Drugs Market Research Report 2024

BUY CHAPTERS

Global Chronic Hepatitis B Treatment Oral Drugs Market Research Report 2026

Code: QYRE-Auto-13N17276

Report

2026-04-13

Pages:111

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novartis

Roche

Merck

Johnson & Johnson

Dawnrays Pharmaceutical

Hansoh Pharmaceutical

Chia Tai-Tianqing Pharmaceutical

Qilu Pharmaceutical

Fujian Cosunter Pharma

Xiamen Amoytop Biotech

YaoPharma

Kelun Pharmaceutical

Chronic Hepatitis B Treatment Oral Drugs Market

The global Chronic Hepatitis B Treatment Oral Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The North American market for Chronic Hepatitis B Treatment Oral Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Chronic Hepatitis B Treatment Oral Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Chronic Hepatitis B Treatment Oral Drugs in Hospital is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Chronic Hepatitis B Treatment Oral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Chronic Hepatitis B Treatment Oral Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chronic Hepatitis B Treatment Oral Drugs. The Chronic Hepatitis B Treatment Oral Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Chronic Hepatitis B Treatment Oral Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Chronic Hepatitis B Treatment Oral Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Chronic Hepatitis B Treatment Oral Drugs Market Report

Report Metric	Details
Report Name	Chronic Hepatitis B Treatment Oral Drugs Market
Segment by Type	Entecavir Tenofovir Lamivudine Adefovir Telbivudine Others
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, Qilu pharmaceutical, Fujian Cosunter Pharma, Xiamen Amoytop Biotech, YaoPharma, Kelun Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Chronic Hepatitis B Treatment Oral Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Hepatitis B Treatment Oral Drugs Market report?

Ans: The main players in the Chronic Hepatitis B Treatment Oral Drugs Market are GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, Qilu pharmaceutical, Fujian Cosunter Pharma, Xiamen Amoytop Biotech, YaoPharma, Kelun Pharmaceutical

What are the Application segmentation covered in the Chronic Hepatitis B Treatment Oral Drugs Market report?

Ans: The Applications covered in the Chronic Hepatitis B Treatment Oral Drugs Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Chronic Hepatitis B Treatment Oral Drugs Market report?

Ans: The Types covered in the Chronic Hepatitis B Treatment Oral Drugs Market report are Entecavir, Tenofovir, Lamivudine, Adefovir, Telbivudine, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Entecavir

1.2.3 Tenofovir

1.2.4 Lamivudine

1.2.5 Adefovir

1.2.6 Telbivudine

1.2.7 Others

1.3 Market by Application

1.3.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Perspective (2021–2032)

2.2 Global Chronic Hepatitis B Treatment Oral Drugs Growth Trends by Region

2.2.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Chronic Hepatitis B Treatment Oral Drugs Historic Market Size by Region (2021–2026)

2.2.3 Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Region (2027–2032)

2.3 Chronic Hepatitis B Treatment Oral Drugs Market Dynamics

2.3.1 Chronic Hepatitis B Treatment Oral Drugs Industry Trends

2.3.2 Chronic Hepatitis B Treatment Oral Drugs Market Drivers

2.3.3 Chronic Hepatitis B Treatment Oral Drugs Market Challenges

2.3.4 Chronic Hepatitis B Treatment Oral Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Revenue

3.1.1 Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Revenue (2021–2026)

3.1.2 Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Chronic Hepatitis B Treatment Oral Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Chronic Hepatitis B Treatment Oral Drugs Revenue

3.4 Global Chronic Hepatitis B Treatment Oral Drugs Market Concentration Ratio

3.4.1 Global Chronic Hepatitis B Treatment Oral Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Hepatitis B Treatment Oral Drugs Revenue in 2025

3.5 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs Head Offices and Areas Served

3.6 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Products and Applications

3.7 Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Chronic Hepatitis B Treatment Oral Drugs Breakdown Data by Type

4.1 Global Chronic Hepatitis B Treatment Oral Drugs Historic Market Size by Type (2021–2026)

4.2 Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Type (2027–2032)

5 Chronic Hepatitis B Treatment Oral Drugs Breakdown Data by Application

5.1 Global Chronic Hepatitis B Treatment Oral Drugs Historic Market Size by Application (2021–2026)

5.2 Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Chronic Hepatitis B Treatment Oral Drugs Market Size (2021–2032)

6.2 North America Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2021–2026)

6.4 North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size (2021–2032)

7.2 Europe Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2021–2026)

7.4 Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size (2021–2032)

8.2 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size (2021–2032)

9.2 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2021–2026)

9.4 Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size (2021–2032)

10.2 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GSK

11.1.1 GSK Company Details

11.1.2 GSK Business Overview

11.1.3 GSK Chronic Hepatitis B Treatment Oral Drugs Introduction

11.1.4 GSK Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.1.5 GSK Recent Development

11.2 Bristol Myers Squibb

11.2.1 Bristol Myers Squibb Company Details

11.2.2 Bristol Myers Squibb Business Overview

11.2.3 Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Introduction

11.2.4 Bristol Myers Squibb Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.2.5 Bristol Myers Squibb Recent Development

11.3 Gilead Sciences

11.3.1 Gilead Sciences Company Details

11.3.2 Gilead Sciences Business Overview

11.3.3 Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Introduction

11.3.4 Gilead Sciences Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.3.5 Gilead Sciences Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Chronic Hepatitis B Treatment Oral Drugs Introduction

11.4.4 Novartis Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.4.5 Novartis Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Chronic Hepatitis B Treatment Oral Drugs Introduction

11.5.4 Roche Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.5.5 Roche Recent Development

11.6 Merck

11.6.1 Merck Company Details

11.6.2 Merck Business Overview

11.6.3 Merck Chronic Hepatitis B Treatment Oral Drugs Introduction

11.6.4 Merck Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.6.5 Merck Recent Development

11.7 Johnson & Johnson

11.7.1 Johnson & Johnson Company Details

11.7.2 Johnson & Johnson Business Overview

11.7.3 Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Introduction

11.7.4 Johnson & Johnson Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.7.5 Johnson & Johnson Recent Development

11.8 Dawnrays Pharmaceutical

11.8.1 Dawnrays Pharmaceutical Company Details

11.8.2 Dawnrays Pharmaceutical Business Overview

11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction

11.8.4 Dawnrays Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.8.5 Dawnrays Pharmaceutical Recent Development

11.9 Hansoh Pharmaceutical

11.9.1 Hansoh Pharmaceutical Company Details

11.9.2 Hansoh Pharmaceutical Business Overview

11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction

11.9.4 Hansoh Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.9.5 Hansoh Pharmaceutical Recent Development

11.10 Chia Tai-Tianqing Pharmaceutical

11.10.1 Chia Tai-Tianqing Pharmaceutical Company Details

11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview

11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction

11.10.4 Chia Tai-Tianqing Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Development

11.11 Qilu pharmaceutical

11.11.1 Qilu pharmaceutical Company Details

11.11.2 Qilu pharmaceutical Business Overview

11.11.3 Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction

11.11.4 Qilu pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.11.5 Qilu pharmaceutical Recent Development

11.12 Fujian Cosunter Pharma

11.12.1 Fujian Cosunter Pharma Company Details

11.12.2 Fujian Cosunter Pharma Business Overview

11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Introduction

11.12.4 Fujian Cosunter Pharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.12.5 Fujian Cosunter Pharma Recent Development

11.13 Xiamen Amoytop Biotech

11.13.1 Xiamen Amoytop Biotech Company Details

11.13.2 Xiamen Amoytop Biotech Business Overview

11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Introduction

11.13.4 Xiamen Amoytop Biotech Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.13.5 Xiamen Amoytop Biotech Recent Development

11.14 YaoPharma

11.14.1 YaoPharma Company Details

11.14.2 YaoPharma Business Overview

11.14.3 YaoPharma Chronic Hepatitis B Treatment Oral Drugs Introduction

11.14.4 YaoPharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.14.5 YaoPharma Recent Development

11.15 Kelun Pharmaceutical

11.15.1 Kelun Pharmaceutical Company Details

11.15.2 Kelun Pharmaceutical Business Overview

11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Introduction

11.15.4 Kelun Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

11.15.5 Kelun Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novartis

Roche

Merck

Johnson & Johnson

Dawnrays Pharmaceutical

Hansoh Pharmaceutical

Chia Tai-Tianqing Pharmaceutical

Qilu Pharmaceutical

Fujian Cosunter Pharma

Xiamen Amoytop Biotech

YaoPharma

Kelun Pharmaceutical

List of Tables

Table 1. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Entecavir

Table 3. Key Players of Tenofovir

Table 4. Key Players of Lamivudine

Table 5. Key Players of Adefovir

Table 6. Key Players of Telbivudine

Table 7. Key Players of Others

Table 8. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 9. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 10. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (US$ Million), 2021–2026

Table 11. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Region (2021–2026)

Table 12. Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

Table 13. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Region (2027–2032)

Table 14. Chronic Hepatitis B Treatment Oral Drugs Market Trends

Table 15. Chronic Hepatitis B Treatment Oral Drugs Market Drivers

Table 16. Chronic Hepatitis B Treatment Oral Drugs Market Challenges

Table 17. Chronic Hepatitis B Treatment Oral Drugs Market Restraints

Table 18. Global Chronic Hepatitis B Treatment Oral Drugs Revenue by Players (US$ Million), 2021–2026

Table 19. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Players (2021–2026)

Table 20. Global Top Chronic Hepatitis B Treatment Oral Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Chronic Hepatitis B Treatment Oral Drugs Revenue, 2025

Table 21. Ranking of Global Top Chronic Hepatitis B Treatment Oral Drugs Companies by Revenue (US$ Million) in 2025

Table 22. Global 5 Largest Players Market Share by Chronic Hepatitis B Treatment Oral Drugs Revenue (CR5 and HHI), 2021–2026

Table 23. Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Headquarters and Area Served

Table 24. Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Products and Applications

Table 25. Global Key Players of Chronic Hepatitis B Treatment Oral Drugs, Date of General Availability (GA)

Table 26. Mergers and Acquisitions, Expansion Plans

Table 27. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Type (US$ Million), 2021–2026

Table 28. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Type (2021–2026)

Table 29. Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

Table 30. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Type (2027–2032)

Table 31. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (US$ Million), 2021–2026

Table 32. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Application (2021–2026)

Table 33. Global Chronic Hepatitis B Treatment Oral Drugs Forecasted Market Size by Application (US$ Million), 2027–2032

Table 34. Global Chronic Hepatitis B Treatment Oral Drugs Revenue Market Share by Application (2027–2032)

Table 35. North America Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2021–2026

Table 37. North America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2027–2032

Table 38. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 39. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2021–2026

Table 40. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2027–2032

Table 41. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 42. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (US$ Million), 2021–2026

Table 43. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size by Region (US$ Million), 2027–2032

Table 44. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2021–2026

Table 46. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2027–2032

Table 47. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 48. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2021–2026

Table 49. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size by Country (US$ Million), 2027–2032

Table 50. GSK Company Details

Table 51. GSK Business Overview

Table 52. GSK Chronic Hepatitis B Treatment Oral Drugs Product

Table 53. GSK Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 54. GSK Recent Development

Table 55. Bristol Myers Squibb Company Details

Table 56. Bristol Myers Squibb Business Overview

Table 57. Bristol Myers Squibb Chronic Hepatitis B Treatment Oral Drugs Product

Table 58. Bristol Myers Squibb Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 59. Bristol Myers Squibb Recent Development

Table 60. Gilead Sciences Company Details

Table 61. Gilead Sciences Business Overview

Table 62. Gilead Sciences Chronic Hepatitis B Treatment Oral Drugs Product

Table 63. Gilead Sciences Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 64. Gilead Sciences Recent Development

Table 65. Novartis Company Details

Table 66. Novartis Business Overview

Table 67. Novartis Chronic Hepatitis B Treatment Oral Drugs Product

Table 68. Novartis Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 69. Novartis Recent Development

Table 70. Roche Company Details

Table 71. Roche Business Overview

Table 72. Roche Chronic Hepatitis B Treatment Oral Drugs Product

Table 73. Roche Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 74. Roche Recent Development

Table 75. Merck Company Details

Table 76. Merck Business Overview

Table 77. Merck Chronic Hepatitis B Treatment Oral Drugs Product

Table 78. Merck Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 79. Merck Recent Development

Table 80. Johnson & Johnson Company Details

Table 81. Johnson & Johnson Business Overview

Table 82. Johnson & Johnson Chronic Hepatitis B Treatment Oral Drugs Product

Table 83. Johnson & Johnson Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 84. Johnson & Johnson Recent Development

Table 85. Dawnrays Pharmaceutical Company Details

Table 86. Dawnrays Pharmaceutical Business Overview

Table 87. Dawnrays Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product

Table 88. Dawnrays Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 89. Dawnrays Pharmaceutical Recent Development

Table 90. Hansoh Pharmaceutical Company Details

Table 91. Hansoh Pharmaceutical Business Overview

Table 92. Hansoh Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product

Table 93. Hansoh Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 94. Hansoh Pharmaceutical Recent Development

Table 95. Chia Tai-Tianqing Pharmaceutical Company Details

Table 96. Chia Tai-Tianqing Pharmaceutical Business Overview

Table 97. Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product

Table 98. Chia Tai-Tianqing Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 99. Chia Tai-Tianqing Pharmaceutical Recent Development

Table 100. Qilu pharmaceutical Company Details

Table 101. Qilu pharmaceutical Business Overview

Table 102. Qilu pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product

Table 103. Qilu pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 104. Qilu pharmaceutical Recent Development

Table 105. Fujian Cosunter Pharma Company Details

Table 106. Fujian Cosunter Pharma Business Overview

Table 107. Fujian Cosunter Pharma Chronic Hepatitis B Treatment Oral Drugs Product

Table 108. Fujian Cosunter Pharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 109. Fujian Cosunter Pharma Recent Development

Table 110. Xiamen Amoytop Biotech Company Details

Table 111. Xiamen Amoytop Biotech Business Overview

Table 112. Xiamen Amoytop Biotech Chronic Hepatitis B Treatment Oral Drugs Product

Table 113. Xiamen Amoytop Biotech Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 114. Xiamen Amoytop Biotech Recent Development

Table 115. YaoPharma Company Details

Table 116. YaoPharma Business Overview

Table 117. YaoPharma Chronic Hepatitis B Treatment Oral Drugs Product

Table 118. YaoPharma Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 119. YaoPharma Recent Development

Table 120. Kelun Pharmaceutical Company Details

Table 121. Kelun Pharmaceutical Business Overview

Table 122. Kelun Pharmaceutical Chronic Hepatitis B Treatment Oral Drugs Product

Table 123. Kelun Pharmaceutical Revenue in Chronic Hepatitis B Treatment Oral Drugs Business (US$ Million), 2021–2026

Table 124. Kelun Pharmaceutical Recent Development

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Authors List of This Report

List of Figures

Figure 1. Chronic Hepatitis B Treatment Oral Drugs Picture

Figure 2. Global Chronic Hepatitis B Treatment Oral Drugs Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Type: 2025 vs 2032

Figure 4. Entecavir Features

Figure 5. Tenofovir Features

Figure 6. Lamivudine Features

Figure 7. Adefovir Features

Figure 8. Telbivudine Features

Figure 9. Others Features

Figure 10. Global Chronic Hepatitis B Treatment Oral Drugs Market Size by Application (US$ Million), 2021–2032

Figure 11. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Application: 2025 vs 2032

Figure 12. Hospital Case Studies

Figure 13. Clinic Case Studies

Figure 14. Others Case Studies

Figure 15. Chronic Hepatitis B Treatment Oral Drugs Report Years Considered

Figure 16. Global Chronic Hepatitis B Treatment Oral Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 17. Global Chronic Hepatitis B Treatment Oral Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 18. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Region: 2025 vs 2032

Figure 19. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Players in 2025

Figure 20. Global Chronic Hepatitis B Treatment Oral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 21. The Top 10 and 5 Players Market Share by Chronic Hepatitis B Treatment Oral Drugs Revenue in 2025

Figure 22. North America Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. North America Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2021–2032)

Figure 24. United States Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Canada Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Europe Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Europe Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2021–2032)

Figure 28. Germany Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. France Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. U.K. Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Italy Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Russia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Ireland Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Asia-Pacific Chronic Hepatitis B Treatment Oral Drugs Market Share by Region (2021–2032)

Figure 36. China Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Japan Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. South Korea Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Southeast Asia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. India Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Australia & New Zealand Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Latin America Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2021–2032)

Figure 44. Mexico Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Brazil Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Middle East & Africa Chronic Hepatitis B Treatment Oral Drugs Market Share by Country (2021–2032)

Figure 48. Israel Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Saudi Arabia Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. UAE Chronic Hepatitis B Treatment Oral Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. GSK Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 52. Bristol Myers Squibb Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 53. Gilead Sciences Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 54. Novartis Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 55. Roche Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 56. Merck Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 57. Johnson & Johnson Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 58. Dawnrays Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 59. Hansoh Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 60. Chia Tai-Tianqing Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 61. Qilu pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 62. Fujian Cosunter Pharma Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 63. Xiamen Amoytop Biotech Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 64. YaoPharma Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 65. Kelun Pharmaceutical Revenue Growth Rate in Chronic Hepatitis B Treatment Oral Drugs Business (2021–2026)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Chronic Hepatitis C Treatment Oral Medicine Market Research Report 2024

Global Chronic Hepatitis C Treatment Drugs Market Research Report 2024

Hepatitis B Virus Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Adult Chronic Hepatitis B Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anti HBV Drugs Market Research Report 2025

Global Oral Anti HBV Drugs Market Research Report 2024

Global Oral Antiviral Medicine Market Research Report 2025

Global Hepatitis B Diagnostic Tests Market Research Report 2024

Anti Hepatitis Virus Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Chronic Hepatitis B Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hepatitis B Treatment Market Insights Forecast to 2030

Hepatitis B Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hepatic Antiviral Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Antiviral Medicines for COVID 19 Market Research Report 2024

Global Oral Azvudine Tablets Market Research Report 2024

Global Hepatitis B Human Immunoglobulin Market Research Report 2024

Hepatitis B Therapeutic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Chronic Liver Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Liver Cancer Treatment Drug Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions